Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?
- 1 September 2005
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 93 (2) , 151-158
- https://doi.org/10.1007/s10549-005-4615-y
Abstract
This study aimed to evaluate patterns of local and distant disease recurrence in patients having primary chemotherapy and compared patterns of relapse in patients with a complete pathological response with those who had residual breast disease. This is an observational study using a sequential series of patients treated with primary chemotherapy. They were followed up for a minimum of 5 years. All data was collected prospectively. Three hundred forty-one consecutive patients with breast cancer were treated with up to eight cycles of doxorubicin-based chemotherapy. Clinical and pathological response rates were evaluated and patients were followed up for disease recurrence (local and distant) and overall survival. Fifty-two patients (16.5%) had a complete pathological response to chemotherapy. Distant disease recurrence occurred in nine patients (17.3%) but no local recurrence was observed. In patients not having a complete pathological response, 86 patients (32.6%) subsequently developed metastases. Local recurrence of disease occurred in 12 (4.5%). There was a statistically significant difference in overall survival between patients whose tumours had a complete pathological response compared with patients who had residual disease in the breast following chemotherapy (88% versus 70% at 5 years, p = 0.036). Following primary chemotherapy, about 84% of patients had residual disease in the breast. Surgery is necessary to ensure complete removal of residual tumour and excellent rates of local control are achievable. A complete pathological response is associated with fewer local and distant recurrences as well as improved survival although there are no differences in time to development of metastatic relapse.Keywords
This publication has 24 references indexed in Scilit:
- Preoperative systemic treatment: prediction of responsivenessThe Breast, 2003
- Is Surgery Necessary After Complete Clinical Remission Following Neoadjuvant Chemotherapy for Early Breast Cancer?Journal of Clinical Oncology, 2003
- Clinical outcome correlation of positron emission tomography (PET) in patients with locally advanced breast cancer (LABC) treated with neoadjuvant doxorubicin and docetaxelInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast CancerNew England Journal of Medicine, 2002
- Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast CancerNew England Journal of Medicine, 2002
- Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast CarcinomaAnnals of Surgery, 2002
- Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapyThe American Journal of Surgery, 1998
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994
- Neoadjuvant chemotherapy in operable breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancerCancer Chemotherapy and Pharmacology, 1978